HCHelen Crowe

Helen Crowe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Helen Crowe has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Anthony J. Costello

    Division of Urology, Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, and Australian Prostate Cancer Research Centre at Epworth Hospital, Richmond

    6 shared publications
  • A. J. Costello

    4 shared publications
  • Justin S. Peters

    Division of Urology, Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, and Australian Prostate Cancer Research Centre at Epworth Hospital, Richmond

    4 shared publications
  • Anthony J. Costello

    Royal Melbourne Hospital

    3 shared publications
  • Michael Kerger

    Division of Urology, Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia

    3 shared publications
  • A Costello

    2 shared publications

Latest Publications

  • Evaluation of a multidisciplinary allied health prostate cancer clinic

    by Helen Crowe, Brindha Pillay, Nicholas Howard, Jane Crowe, Max Rutherford, Addie Wootten, Niall Corcoran, Anthony Costello

    Prostate cancer is the most common male cancer, with increasingly longer survival, and many treatment options for advanced disease. Men with prostate cancer report a high level of unmet supportive care needs. To evaluate unmet needs of a small cohort of Australian men with advanced prostate cancer, and their partners, and to assess the impact of attendance at a multidisciplinary allied health clinic on meeting these needs. Fifty patients were referred to the clinic by their treating specialists. Prior to their clinic consultations patients and partners completed study questionnaires to determine their unmet needs, prostate cancer and treatment related quality of life, levels of anxiety and depression, exercise patterns and prostate cancer‐related functional status. Questionnaires were completed again 1 month post‐clinic attendance, and pre‐and post‐clinic scores were compared. Patients reported unmet needs in several domains including psychological and sexuality needs. These showed a small reduction when assessed post‐clinic. Partners also reported needs in the psychological and emotional, and information domains. Thirty‐two percent of patients reported clinical levels of distress when assessed pre‐clinic attendance, reduced to 8% reporting the same level of distress 1 month post‐clinic. The identified high levels of unmet needs and levels of distress of this group of patients and partners highlights the necessity for additional resources to assist these men. A multidisciplinary allied health care prostate clinic as described here may further assist in the comprehensive care of these men and their partners.

  • Prostate cancer multidisciplinary care: improving patient outcomes

    by Philip E. Dundee, Lih-Ming Wong, Niall Corcoran, Addie C. Wootten, Helen Crowe, David Sandall, Adam Dowrick, Patrick Bowden, Ben Tran, Jane Crowe, et al.

  • Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis

    by Michael Kerger, Matthew K.H. Hong, John Pedersen, Timothy Nottle, Andrew Ryan, John Mills, Justin S. Peters, Daniel Moon, Helen Crowe, Anthony J. Costello, et al.


  • Robotic radical prostatectomy as the initial step in multimodal therapy for men with high‐risk localised prostate cancer: initial experience of 160 men

    by Stephen S. Connolly, Paul J. Cathcart, Paul Gilmore, Michael Kerger, Helen Crowe, Justin S. Peters, Declan G. Murphy, Anthony J. Costello

    Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? The choice of therapy with high‐risk localised prostate cancer is difficult and, in the stark absence of any randomised trials, comparative retrospective analyses of case series continue to be necessary. Radical surgery has been considered by many to be inferior to a combination of radiotherapy (RT) and androgen deprivation therapy (ADT), but this changing perhaps coincidentally with the widespread acceptance of robot‐assisted laparoscopic prostatectomy surgery (RALP). Further evidence has now described the long‐term toxicities related to ADT, and this has strengthened a desire amongst many to at least defer, if not avoid, ADT unless absolutely necessary. This article presents a single‐centre experience of RALP in the setting of high‐risk localised disease, and concludes that RALP incorporating the use of post‐operative RT represents a strong perhaps optimum management strategy. OBJECTIVES: To report the outcome of robotic‐assisted laparoscopic radical prostatectomy (RALP) for men with localised high‐risk prostate cancer at diagnosis. Although commonly managed by radiotherapy (RT) with prolonged androgen‐deprivation therapy (ADT), we hypothesize that initiation of multimodal therapy with RALP is oncologically efficacious and may allow many men to avoid ADT. PATIENTS AND METHODS: Between December 2003 and September 2010, 1480 men underwent RALP of whom 160 fulfilled the National Comprehensive Control Network criteria for high‐risk disease (prostate‐specific antigen (PSA) >20 ng/mL and/or clinical stage, cT ≥ 3 and/or biopsy Gleason score ≥8). Biochemical recurrence (postoperative PSA ≥ 0.2) was used to assess outcome after RALP monotherapy. Treatment failure was defined as either a rising PSA level after salvage RT or the initiation of ADT. RESULTS: The mean age ± standard deviation was 63.1 ± 6.3 years. Median PSA level was 9.95 ng/mL (interquartile range 6.0–21.4). Analysis of prostatectomy specimen showed Gleason 8–10 cancers in 65 (41%), and extracapsular disease, pT ≥ 3, in 96 (60%) of which seminal vesicle invasion was evident in 36 (23%). Downgrading by prostatectomy occurred in 64 (40% of total group) and five (3%) were downstaged to pT2 disease. By contrast, any upgrading occurred in 29 (18% of total group) and upstaging occurred in 68 (43%). The overall positive surgical margin rate was 38%, correlating with stage pT2 (15%) or pT3 (53%). With median follow‐up of 26.2 months (interquartile range 5.5–37.3), two non‐cancer‐related deaths have occurred (overall survival 98.8%; cancer‐specific survival 100%), and biochemical recurrence has occurred in 53 men (33%). RALP surgery has served as monotherapy ( n = 117, 73%), or has been followed by salvage RT ( n = 24, 15%) and/or ADT ( n = 43, 27%). Overall 2‐year and 3‐year treatment failure was 31 and 41%, respectively. Serum PSA level was the only independent predictor of overall treatment failure (hazard ratio [HR] 1.02, P = 0.001) although a strong trend was observed for both clinical stage (HR 1.22, P = 0.058) and the number of positive biopsy cores on transrectal biopsy (HR 1.06, P = 0.057). CONCLUSIONS: RALP incorporating the use of postoperative RT is a good multimodal management strategy for men with this aggressive variant of prostate cancer. At median follow‐up in excess of 2 years, we found low rates of treatment failure enabling a high proportion of men to remain free of ADT.


  • A randomized trial of photoselective vaporization of the prostate using the 80‐W potassium‐titanyl‐phosphate laser vs transurethral prostatectomy, with a 1‐year follow‐up

    by David M. Bouchier‐Hayes, Scott Van Appledorn, Pat Bugeja, Helen Crowe, Ben Challacombe, Anthony J. Costello

    Study Type – Therapy (RCT) Level of Evidence 2b OBJECTIVE: To compare the potassium‐titanyl‐phosphate Greenlight TM 80‐W laser ablation system for photovaporization of the prostate (PVP; Laserscope, San Jose, CA, USA) with transurethral resection of the prostate (TURP), as many technologies have been proposed as equivalent or superior to TURP without gaining widespread acceptance, due to lack of data from randomized trials. PATIENTS AND METHODS: In all, 120 patients were randomized to undergo either TURP or PVP after a full urological evaluation, which was repeated at 1, 3, 6 and 12 months after surgery. Irrigation use, duration of catheterization (DOC), length of hospital stay (LOS), blood loss, cost and operative time were also assessed. RESULTS: Both groups showed a significant increase in mean ( sd ) maximum urinary flow rate from baseline ( P < 0.05); in the TURP group from 8.9 (3.0) to 19.4 (8.7) mL/s (154%), and in the PVP group from 8.8 (2.5) to 18.6 (8.2) mL/s (136%). The International Prostate Symptom Score (IPSS) decreased from 25.4 (5.7) to 10.9 (9.4) in the TURP group (53%), and from 25.3 (5.9) to 8.9 (7.6) in the PVP group (61%). The trends were similar for the bother and Quality of Life scores. There was no difference in sexual function as measured by Baseline Sexual Function Questionnaires. The DOC was significantly less in the PVP than the TURP group ( P < 0.001), with a mean (range) of 13 (0–24) h vs 44.7 (6–192) h. The situation was similar for LOS ( P < 0.001), with a mean (range) of 1.09 (1–2) and 3.6 (3–9) days in the PVP and TURP groups, respectively. Adverse events and complications were less frequent in the PVP group. Costs were also 22% less in the PVP group. CONCLUSIONS: This trial shows that PVP is an effective technique when compared to TURP, producing equivalent improvements in flow rates and IPSS with the advantages of markedly reduced LOS, DOC and adverse events. A long‐term follow‐up is being undertaken to ensure durability of these results.


  • Robotic radical prostatectomy in Australia: initial experience

    by O’malley, P. J., S. Van Appledorn, D. M. Bouchier-Hayes, H. Crowe, A. J. Costello

    The purpose of this study is to describe the initial experience of robotic-assisted radical prostatectomy (RARP) in Australia. Since the installation of the daVinci® system at the Australian Institute for Robotic Surgery, Epworth Hospital, Melbourne in December 2003, 275 robotic-assisted radical prostatectomies have been performed by two surgeons. A prospective database is compiled for each procedure including patient, operative and outcome details. We report on the initial learning curve, surgical technique and modifications, anaesthetic considerations and surgical results comparative to open radical prostatectomy in a single surgeons experience along with margin positivity rates for the first 200 cases of RARP. RARP is the single most frequent adaptation of robotic-assisted surgery with promising initial results. Increasing availability of this modality will inevitably give rise to further adaptations. We present the initial Australian experience.


  • Installation of telerobotic surgery and initial experience with telerobotic radical prostatectomy

    by Anthony J. Costello, Hodo Haxhimolla, Helen Crowe, Justin S. Peters

    OBJECTIVE: To assess the ability of untrained laparoscopic surgeons to learn and implement laparoscopic telerobotic radical prostatectomy (TRP) using the daVinci Surgical System (Intuitive Surgical, CA), and assess the education, safety and efficacy issues when instituting this system. PATIENTS AND METHODS: Between December 2003 and October 2004, 122 consecutive TRPs were performed by two surgeons for clinically localized prostate cancer. The individual robotic surgeon was assisted at the bedside by another surgeon. The TRP was performed robotically by the surgeon at the remote console unit. Perioperative data and pathological results were recorded. The two surgeons spent 1 week in a skills laboratory using a porcine model of laparoscopic TRP, and then cadaveric robotic prostatectomy. The first six cases were mentored by an experienced telerobotic surgeon. RESULTS: The TRP was conducted by two surgeons with no previous laparoscopic experience. There were no conversions to open surgery. Assessing the complications, postoperative continence, operating time and transfusion rates showed equivalent efficacy and safety to open and pure laparoscopic methods. CONCLUSION: TRP represents a novel computer‐based surgical approach to prostate cancer, which offers the benefits of minimally invasive surgery without the extensive experience associated with the laparoscopic method. It remains to be seen whether the robotic approach can deliver better outcomes in continence and potency over time.